Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10369304 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL736509 | 0.97 | — | — | |
| SCHEMBL16684352 | 0.92 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL10367667 | 0.90 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL13831932 | 0.89 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL20272747 | 0.85 | — | — | |
| SCHEMBL11310258 | 0.85 | HRH3 (0.60) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL5440143 | 0.82 | — | — | |
| SCHEMBL23828672 | 0.82 | HRH3 (0.81) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL4519052 | 0.82 | HRH3 (0.81) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10640502-B2 | Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) | NORTHWESTERN UNIVERSITY (US) | 2020-05-05 | — | — | US | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170305901-A1 | THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r) | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | disclosed |
| US-9701678-B2 | Small-molecule HSP90 inhibitors | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170182023-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, KITS AND/OR METHODS THEREOF | SAVANNAH STATE UNIVERSITY | 2017-06-29 | — | — | US | disclosed |
| US-9532983-B2 | Benzofuran compounds, compositions, kits and/or methods thereof | SAVANNAH STATE UNIVERSITY (US) | 2017-01-03 | — | — | US | disclosed |
| EP-1689395-B1 | VINCA DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20150133498-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, KITS AND/OR METHODS THEREOF | SAVANNAH STATE UNIVERSITY | 2015-05-14 | — | — | US | disclosed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-4751302-A | ANTIINFLAMMATORY, ANTIULCER AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4585869-A | ANTIINFLAMMATORY, ANALGESIC, ANTIULCER | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-04-29 | — | — | US | disclosed |
| US-4549023-A | ANTINFLAMMATORY AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-10-22 | — | — | US | disclosed |
| US-4533731-A | ANTIINFLAMMATORY AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-08-06 | — | — | US | disclosed |
| EP-0049779-B1 | 3-AMINOINDAZOLE DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4474964-A | 3-Aminoindazole derivatives | ASAHI, KASEI, KOGYO, KABUSHIKI, KAISHA (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0090972-A2 | Indazole derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-10-12 | — | — | EP | disclosed |
| EP-0049779-A1 | 3-Aminoindazole derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-04-21 | — | — | EP | disclosed |
| US-3969392-A | PARASITICIDE, BACTERICIDE, ANTIINFLAMMATORY, SURFACTANT | E. R. SQUIBB & SONS, INC. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3935230-A | α, α, α, α', α', α'-Hexafluorodi-m-tolylamine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133498-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, KITS AND/OR METHODS THEREOF | SIGMAR1, OPRM1, OPRL1 | HRH3 252/4885CYP1A2 194/4885MAPK1 3888/4885 |
| US-20170305901-A1 | THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r) | IRAK4, IRAK1, IRAK2 | HRH3 1408/4885CYP1A2 4642/4885MAPK1 155/4885 |
| US-20170182023-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS, KITS AND/OR METHODS THEREOF | SIGMAR1, OPRM1, OPRL1 | HRH3 252/4885CYP1A2 194/4885MAPK1 3888/4885 |
| US-10640502-B2 | Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) | IRAK4, IRAK1, IRAK2 | HRH3 1408/4885CYP1A2 4642/4885MAPK1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.